2026年A股首个交易日，三大指数放量上涨。 同花顺（300033）数据显示，脑机接口、医疗、存储芯片等板块今日表现活跃，海南自贸区、免税店、旅游及酒店等板块表现较弱。 今日，存储芯片龙头股兆易创新（603986）主力资金净流入达20.46亿元，位居A股第一名，也是今日唯一一只净流入超20亿元的个股。截至收盘，兆易创 新涨停，报235.68元/股，总市值达1574亿元。2025年，兆易创新股价涨幅达101.17%。 | 兆易创新 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 603986 融 沪股通 L1 | | | | | | | | 235.68 235.68 | | ■ | | 市值 1574.0亿 | 1.69 量比 | | | 221.00 | | | | 流通 1574.0亿 | 7.48% 换 | | | 21.43 10.00% 221.32 | | 开 | | 市盈 TIM 116.28 | 额 115.61亿 | | | 相关 ETF > | | | | 芯片 ETF 广发 4.55% 含兆易创新 6.8% > | ...

Market Overview - On the first trading day of 2026, the three major indices in A-shares experienced significant gains, with the Shanghai Composite Index rising by 1.38% and returning to the 4000-point mark, while the Shenzhen Component Index and the ChiNext Index increased by 2.24% and 2.85% respectively. The total market turnover reached approximately 2.57 trillion yuan, an increase of over 500 billion yuan compared to the previous trading day, with more than 4100 stocks rising [2]. Sector Performance - The storage chip sector showed strong performance, with leading stock Zhaoyi Innovation seeing a net inflow of 2.046 billion yuan, the highest in A-shares, and closing at a limit-up price of 235.68 yuan per share, giving it a total market capitalization of 157.4 billion yuan. Zhaoyi Innovation's stock price increased by 101.17% in 2025 [4][6]. - Other stocks in the storage chip sector, such as Hengluo Co., Yunhan Chip City, and Puran Co., also reached their daily limit-up prices, indicating a robust rally in this sector [6]. Price Trends and Forecasts - According to research from Guojin Securities, the prices of storage chips are expected to surge due to strong AI demand, with DDR4 16Gb prices projected to rise by 1800%, DDR5 16Gb by 500%, and 512Gb NAND flash by 300% in 2025. The global demand for storage chips is anticipated to remain high in 2026, leading to continued price increases [9]. - Research from招商证券 indicates that the expansion of storage and advanced process capacities driven by AI demand will accelerate in 2026-2027, benefiting domestic equipment manufacturers with a strong order flow [9]. Brain-Computer Interface Sector - The brain-computer interface sector experienced a significant surge, with stocks like Beiyikang and Botao Bio reaching their daily limit-up prices. This sector was the top performer on the Tonghuashun gainers list [10][11]. - The announcement by Elon Musk regarding Neuralink's plans to start large-scale production of brain-computer interface devices in 2026, along with nearly fully automated surgical procedures, marks a significant milestone for the sector, transitioning it from a "medical trial tool" to a "widely available product" [11]. Market Outlook - According to招商证券, the A-share market is expected to continue its upward trend in January, with an increased probability of hitting new highs. Factors contributing to this outlook include accelerated issuance of local government special bonds and improved government spending and investment data [15]. - The report suggests that the focus in January will be on performance disclosures, with particular attention to sectors such as commercial aerospace, AI applications, AI computing power, and semiconductor equipment, as well as consumer services and non-bank financials [16].

| 300143 | 盈康生 命 | 15.18 | 7.38 | 10.23 | 11.38 | 11.28 | | --- | --- | --- | --- | --- | --- | --- | | | 泰和科 | | | | | | | 300801 | 技 | 15.49 | 20.84 | 28.75 | 31.91 | 10.98 | （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 920199 | 倍益康 | 29.98 | 12.94 | 37.83 | 44.96 | 18.85 | | 920925 | 锦好医 疗 | 20.03 | 19.58 | 33.00 | 38.23 | 15.84 | | 688580 | 伟思医 疗 | 20.00 | 7.33 | 50.50 | 58.08 | 15.01 | | 300430 | 诚益通 ...

开源证券认为，脑机接口将定义人形机器人的人机交互新范式，探索人脑作为机器人大脑可能性，构建 人机融合的终极生态。近期脑机接口利好不断，印证了脑机接口技术预计将在2026年迈向商业化，并从 医疗刚需向AI应用、机器人等多领域渗透。根据PrecedenceResearch数据，预计到2034年全球脑机接口 市场规模将增长到约124亿美元，2025-2034年CAGR为17%。 （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 消息面上，据新华社报道，美国企业家埃隆·马斯克2025年12月31日在社交媒体上表示，其脑机接口公 司"神经连接"将于2026年开始对脑机接口设备进行"大规模生产"，并转向"更加精简和几乎完全自动化 的外科手术流程"。马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 1月5日，市场高开高走迎来2026年开门红，创业板指领涨，沪指重回4000点上方，录得十二连阳。板块 方面，脑机接口掀起涨停潮，指数大涨超13%；个股上，倍益康30cm涨停，另有博拓生物、三博脑 科、爱朋医疗等15只概念股20cm涨停，12只概念股10cm涨停。 ...

1月5日，A股市场高开高走迎来2026年开门红，创业板指领涨，沪指重回4000点上方。截至收盘，沪指涨1.38%，录得十二连阳，深成指涨2.24%，创业板 指涨2.85%。全市场成交额高达2.57万亿，较上一个交易日放量5015亿，近4200只个股上涨，其中127只个股涨停。 消息面上，据智通财经报道，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进行"大规模生产"。 21世纪经济报道记者获悉，去年年初，国家医保局发布对脑机接口康复收费的指导意见，直接推动了脑机接口产业快速发展。目前已有约11个省市出台脑 机接口相关收费标准，且不少公司也透露最新商业化进展。 午后贵金属板块持续走强，兴业银锡封涨停，此前湖南白银涨停，西部黄金、山东黄金等涨幅靠前。消息面上，贵金属市场受突发地缘政治事件催化，现 货白银日内一度涨超5%，站上75美元大关，此外现货黄金日内涨超2%，收复4400美元关口。 板块方面，脑机接口概念全天领涨，三十余只成分股涨停。保险板块爆发，新华保险、中国太保大涨续创历史新高。商业航天概念反复活跃，雷科防务4 连板，中国卫通5天3板。半导体产业链走强，亚翔集 ...

Market Performance - The A-share market experienced a "good start" on the first trading day of the new year, with the Shanghai Composite Index rising over 1% and surpassing the 4000-point mark [1] - The technology growth sector led the gains, particularly in the electronics and pharmaceutical biotechnology sectors, with multiple stocks hitting the daily limit [3] - Non-bank financial sectors, especially insurance stocks, also showed strong performance, while sectors like oil and banking experienced adjustments [3] Brain-Computer Interface Sector - The brain-computer interface (BCI) concept sector performed exceptionally well, with stocks like BeiYikang hitting a 30% limit up, and several others, including BoTuo Bio and Sanbo Neuroscience, reaching 20% limit up [3] - Elon Musk announced plans for large-scale production of BCI devices by his company Neuralink, which aims to streamline surgical processes and enhance device control capabilities [3] - Domestic companies are actively engaging in BCI business, with Meihao Medical collaborating with BCI clients, and Xiangyu Medical planning to expand its BCI project to over 700 medical institutions by early 2026 [4] Company Developments - Meihao Medical indicated that artificial cochlear implants are a significant application direction for BCI, although current revenue from this business is still small [4] - Xiangyu Medical aims to establish a comprehensive product matrix for BCI by entering over 1000 top-tier hospitals within the year [4] - Entropy Technology is focusing on developing next-generation BCI algorithms and advancing hybrid biometric recognition and brain signal analysis [4] Hong Kong Market Activity - In the Hong Kong market, BCI-related stocks also showed significant activity, with Nanjing Panda Electronics rising over 40% and other stocks like Micro-Innovation Brain Science experiencing substantial gains [4]

随着马斯克明确给出脑机接口设备的量产时间表，这一前沿赛道正从实验室的科学探索加速走向商业化落地，行业或将迎来从"医疗试验品"向"大 众消费品"跨越的关键转折点。 2026年A股开盘首日，脑机接口板块表现强势。倍益康30CM涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通、伟思医疗等多股20CM 涨停，市场资金对脑机接口商业化前景展现出极高预期。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | 涨跌 | 换手率 | | --- | --- | --- | --- | --- | --- | | 688108 | 賽诺医疗 | 23.09 | 20.01% | 3.85 | 14.83% | | 300238 | 冠昊生物 | 16.62 | 20.00% | 2.77 | 13.53% | | 300753 | 爰朋医疗 | 33.30 | 20.00% | 5.55 | 21.10% | | 301363 | 美好医疗 | 28.86 | 20.00% | 4.81 | 1.93% | | 688626 | 翔宇医疗 | 72.60 | 20.00% | 12.10 | 3.36% | | 300003 ...

Core Viewpoint - The brain-computer interface (BCI) industry is experiencing rapid growth, driven by advancements in technology and supportive government policies, with significant developments expected by 2026 when large-scale production is set to begin [2][3]. Industry Developments - Neuralink plans to start mass production of BCI devices in 2026, utilizing nearly fully automated surgical processes [2]. - The BCI index in the A-share market rose by 9.37%, with over 20 stocks, including companies like Botao Bio and Sanbo Brain Science, hitting the daily limit [2]. - The National Healthcare Security Administration (NHSA) has issued guidelines for BCI rehabilitation charges, which has accelerated the industry's growth [2]. Policy Support - The 14th Five-Year Plan identifies BCI as one of six key future industries, with specific pricing projects established for both invasive and non-invasive BCI technologies [3]. - New regulations from the NHSA in September 2025 will facilitate the coding of innovative medical products, further promoting BCI clinical applications [3]. Technological Breakthroughs - China has made significant strides in invasive BCI technology, becoming the second country globally to enter clinical trials for invasive BCI systems [4]. - The "North Brain No. 1" GCP multi-center clinical trial, set to launch in October 2025, will be the first to implement a high-throughput, wireless, semi-invasive BCI system with over 100 channels [4]. Competitive Landscape - The BCI industry in China is competitive, with the potential to lead globally, as companies focus on serving downstream clients, including hospitals and patients [5]. - The BCI industry has established a complete supply chain, covering upstream materials and chips, midstream signal processing, and downstream applications in healthcare and consumer products [6]. Regulatory Focus - BCI products, especially invasive types, are classified as high-risk medical devices, necessitating strict regulatory oversight [8]. - Companies like Xiangyu Medical and Aipeng Medical are actively pursuing product registrations for various BCI applications, including rehabilitation and monitoring systems [8][9].

Market Overview - The Shanghai Composite Index closed at 4018.63 points, above the five-day moving average, with an increase of 1.25% [1] - The total trading volume of A-shares reached 24,812.35 billion yuan [1] Stocks Performance - A total of 1,955 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - BeiYikang (18.85% deviation rate, 29.98% increase, latest price 44.96 yuan) [1] - WeiSi Medical (15.01% deviation rate, 20.00% increase, latest price 58.08 yuan) [1] - ChengYiTong (14.78% deviation rate, 19.98% increase, latest price 23.06 yuan) [1] Additional Notable Stocks - Other stocks with significant performance include: - GuanHao Biological (14.72% deviation rate, 20.00% increase, latest price 16.62 yuan) [1] - DiNaiKe (14.64% deviation rate, 20.00% increase, latest price 17.76 yuan) [1] - MeiHao Medical (14.46% deviation rate, 20.00% increase, latest price 28.86 yuan) [1] Trading Metrics - The trading turnover rates for the top performing stocks vary, with BeiYikang at 12.85% and WeiSi Medical at 7.20% [1] - The five-day moving average prices for these stocks range from 14.49 yuan to 282.35 yuan [1][2]

Core Viewpoint - The A-share market experienced a significant upward movement on the first trading day of 2026, with the Shanghai Composite Index rising over 1% and surpassing the 4000-point mark, driven by a surge in brain-computer interface (BCI) stocks [1] Group 1: Market Performance - The combined trading volume of the Shanghai and Shenzhen markets exceeded 1.6 trillion yuan, indicating a notable increase in market activity [1] - Several BCI-related stocks, including Sanbo Brain Science, Aipeng Medical, and others, reached the daily limit of a 20% increase [1][2] Group 2: Industry Insights - Elon Musk's recent comments regarding Neuralink's plans to mass-produce BCI devices by 2026 have sparked interest in the BCI sector, with expectations of significant advancements in technology and applications [3] - The global BCI market is projected to grow from $2.94 billion in 2025 to $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034 [3] - Recent research breakthroughs in medical applications such as movement recovery and communication have been reported, supported by favorable policies from the government, including separate pricing for new BCI technologies [4]